首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1983144

免疫查核点抑制剂市场：依药物类别、癌症类型、通路和地区划分

Immune Checkpoint Inhibitors Market, By Drug Class, By Cancer Type, By Distribution Channel, By Geography

出版日期: 2026年02月19日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到2026年，免疫查核点抑制剂市场规模将达23.696亿美元，2033年将达到56.156亿美元。预计从2026年到2033年，其复合年增长率将达到13.2%。

报告范围		报告详情
基准年：	2025	2026年市场规模：	23.696亿美元
历史数据时期：	2020年至2024年	预测期：	2026年至2033年
2026年至2033年预测期间的复合年增长率：	13.20%	2033年市场规模预测：	56.156亿美元

免疫查核点抑制剂是免疫肿瘤疗法的一部分，利用患者自身的免疫系统攻击癌细胞。免疫肿瘤疗法采用新型免疫疗法，例如免疫查核点抑制剂，来活化患者的免疫系统。这些疗法针对的是人体的免疫系统而非肿瘤本身，使免疫系统能够识别并攻击癌细胞。免疫查核点抑制剂是一种免疫治疗产品，它能够抑制阻止免疫系统攻击癌细胞的蛋白质。这些药物抑制特定的查核点蛋白，例如 CTLA-4、PD-1 和 PD-L1。製造商正在研发免疫查核点抑制剂，用于联合治疗。免疫查核点抑制剂对多种癌症有效，包括非小细胞肺癌、淋巴瘤、皮肤癌和乳癌。根据其作用机制，这些治疗方法进一步分为程序性死亡受体-1 (PD-1) 抑制剂、程序性死亡配体-1 (PD-L1) 抑制剂和细胞毒性T淋巴细胞抗原4 (CTLA-4) 抑制剂等亚型。市售的免疫查核点抑制剂包括Ipilimumab、Nivolumab、Rituximab、Blinatumomab、普罗莱Proleukin、Gardasil和凯姆瑞。

市场动态

癌症发生率的上升预计将推动全球免疫查核点抑制剂市场的发展。例如，根据美国癌症协会预测，2022年美国将新增1918,030例癌症病例，并有609,360例癌症相关死亡病例，其中肺癌是癌症死亡的主要原因，每天约有350人死于肺癌。 2022年，中国和美国预计分别新增约482万例癌症病例和237万例癌症病例，以及321万例和64万例癌症相关死亡病例。（2022年新增癌症病例和死亡病例估计：2022年，美国预计新增癌症病例190万例，癌症相关死亡病例609360例。）

本次调查的主要特点。

本报告对全球免疫查核点抑制剂市场进行了详细分析，以 2021 年为基准年，给出了预测期（2022-2030 年）的市场规模和复合年增长率。
本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本报告根据以下参数对全球免疫查核点抑制剂市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
透过利用本报告中提出的见解，企业行销负责人和经营团队将能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
本报告面向该产业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
透过对全球免疫查核点抑制剂市场进行分析时所使用的各种策略矩阵，相关人员将能够更轻鬆地做出决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
中东
- GCC
- 以色列
- 其他中东国家
非洲
- 北非
- 中非
- 南非

第八章竞争情势

热图分析
公司简介
- Bristol-Myers Squibb Company
- Merck &Co., Inc.
- F. Hoffmann-La Roche AG
- AstraZeneca Plc
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.

第九章

参考
调查方法

简介目录

Product Code: CMI2560

Immune Checkpoint Inhibitors Market is estimated to be valued at USD 2,369.6 Mn in 2026 and is expected to reach USD 5,615.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,369.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.20%	2033 Value Projection:	USD 5,615.6 Mn

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)

Key features of the study

This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immune checkpoint inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market

Market Segmentation

By Drug Class
- Programmed Death Receptor-1 (PD-1) Inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Cemiplimab (Libtayo)
- Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
- Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer
- Melanoma
- Merkel Cell Carcinoma
- Blood Cancer
- Lymphoma
- Bladder Cancer
- Urothelial Carcinoma
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- AstraZeneca Plc.
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Epidemiology
Collaborations & Partnerships
Major FDA Approvals & Product Launch Scenario
Pipeline Analysis
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Programmed Death Receptor-1 (PD-1) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Pembrolizumab (Keytruda)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Nivolumab (Opdivo)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Cemiplimab (Libtayo)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Atezolizumab (Tecentriq)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Avelumab (Bavencio)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Durvalumab (Imfinzi)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
CTL-4 Checkpoint Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Ipilimumab (Yervoy)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Lymphocyte-Activation Gene 3 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global Immune Checkpoint Inhibitors Market, By Cancer Type, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Head & Neck Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Blood Cancer (Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Bladder Cancer (Urothelial Carcinoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Renal/Kidney Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global Immune Checkpoint Inhibitors Market, By Region, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- F. Hoffmann-La Roche AG
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AstraZeneca Plc
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis International AG
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- ImmunOs Therapeutics AG
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Immutep Ltd.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- NewLink Genetics Corporation
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Ono Pharmaceutical Co., Ltd.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Introduction
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

免疫查核点抑制剂市场：依药物类别、癌症类型、通路和地区划分

Immune Checkpoint Inhibitors Market, By Drug Class, By Cancer Type, By Distribution Channel, By Geography

市场动态